Original language | English (US) |
---|---|
Pages (from-to) | 8227-8228 |
Number of pages | 2 |
Journal | Vaccine |
Volume | 28 |
Issue number | 52 |
DOIs | |
State | Published - Dec 6 2010 |
ASJC Scopus subject areas
- Molecular Medicine
- General Immunology and Microbiology
- General Veterinary
- Public Health, Environmental and Occupational Health
- Infectious Diseases
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Vaccine, Vol. 28, No. 52, 06.12.2010, p. 8227-8228.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Developing the next generation of vaccinologists
AU - Poland, Gregory A.
AU - Levine, Myron M.
N1 - Funding Information: Within the United States for example, only one formally organized academic program in vaccine sciences exists. This program is an NIH-funded (T32) vaccinology training grant at the Center for Vaccine Development (CVD) at the University of Maryland. The program (which typically involves 3–4 years of post-doctoral training), includes three distinct tracks. One track provides training in basic research involving the stage of discovery and preparation of vaccine candidates through animal model evaluation and accumulation of the pre-clinical data necessary to support an Investigational New Drug application to the U.S. FDA to undertake “first in humans” clinical trials. A second track involves training in the design and performance of Phase 1 and 2 clinical trials, including intensive didactic and practical instruction in Good Clinical Practices, maintenance of INDs and strategies and options for paths to licensure. A third track involves the design and performance of large-scale Phase 3 pre-licensure efficacy trials and Phase 4 post-licensure studies to assess the impact and safety of vaccines when implemented in large populations; this track includes training in data management, analysis and biostatistics. The NIH-funded Vaccinology Training Program interacts with other activities within CVD, such as basic research projects supported by R01 and other grants, clinical trials of various vaccines supported by a NIH Vaccine and Treatment Evaluation Unit, N01 research contracts, various basic and translational projects supported by the Middle Atlantic Regional Center for Excellence in Biodefense and Emerging Infectious Diseases Research, and field epidemiologic and vaccine field trial studies supported by the Bill and Melinda Gates Foundation, including at CVD's field units in Mali, Chile and Malawi. A limitation of the T32 grant is its restriction to U.S. citizens or permanent residents. Therefore, trainees from abroad are supported by other sources of training funds.
PY - 2010/12/6
Y1 - 2010/12/6
UR - http://www.scopus.com/inward/record.url?scp=78649743324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649743324&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2010.11.001
DO - 10.1016/j.vaccine.2010.11.001
M3 - Editorial
C2 - 21129602
AN - SCOPUS:78649743324
SN - 0264-410X
VL - 28
SP - 8227
EP - 8228
JO - Vaccine
JF - Vaccine
IS - 52
ER -